History of Cialis

Years of testing was done on the drug Tadalafil prior to the inception of the brand name “Cialis”, or the function being to aid those suffering from sexual dysfunction. GlaxoSmithKline, formerly Glaxo Wellcome, in conjunction with Icos Corporation, both of which are pharmaceutical companies, studied IC351 together for other various functions and purposes beginning in 1993.

About Icos Corporation

Icos Corporation, or ICOS, was founded in 1989 as a biotechnology company specifically concerned with the clinical investigation of drugs which, when developed, would hopefully treat inflammatory disorders such as multiple sclerosis, acute respiratory distress syndrome, rheumatoid arthritis, and chronic obstructive pulmonary disease. With seventeen years of experience in the industry, ICOS was able to conduct clinical trials on twelve drugs, one of which being tadalafil.

About GSK

GSK, or GlaxoSmithKline, one of the largest pharmaceutical companies in the world today, began in the year 2000 in Brentford, London when the company GlaxoWellcome merged with SmithKline. The company Glaxo Wellcome has a long history beginning as a general trading company in 1873 called Joseph Nathan and Co. Glaxo Wellcome, the company that merged with ICOS to test tadalafil, was formed in 1995 with the merger of Glaxo and Wellcome that cut back on expenses and expenditures to move the company in a more profitable direction.

Glaxo Wellcome and its many forms pre and post mergers is responsible in some part for amoxicillin, zidovudine for HIV, lamotrigine for epilepsy, thioguanine which it utilised to treat leukemia, and even valacyclovir for herpes virus infections. They are focused primarily on the manufacturing of medications aimed at major disease treatment. At the time of the partnership with Icos Corporation, Glaxo Wellcome was beginning their 1995 restructuring, which occurred shortly before their rise to success as the third largest pharmaceutical company in the world in 1999.

Partnership

With the partnership of Glaxo Wellcome and Icos Corporation began the clinical study of the drug tadalafil as a possible treatment for inflammatory disorders or heart conditions in 1993. After a year of testing for various functions and purposes, this PDE5, or phosphodiesterase type 5 enzyme inhibitor, was shown in 1994 studies to induce penile erection in men.

As a result of this accidental discovery, ICOS and Glaxo Wellcome began testing on the drug specifically for the purpose of inducing or increasing erectile function. The companies created and received a patent for IC351, which meant that studies could be furthered beginning the next year, with Phase 1 clinical trials of the drug taking place in 1995 and 1996.

The Exit of Glaxo Wellcome & New Partnership

As 1996 came to a close, Glaxo Wellcome moved out of the partnership due to a commitment to core markets. The function of IC351 as a medication for erectile dysfunction, while ground-breaking, was not within their company’s core markets. The agreement would have granted Glaxo half of the profits for what would soon be Cialis. Phase 2 clinical studies then occurred throughout 1997 solely conducted by ICOS, followed by Phase 3 trials.

In order to continue development on this new drug, ICOS Corporation joined forces with Eli Lilly and Company in 1998. This partnership culminated in the company Lilly ICOS, LLC. Eli Lilly and Company, which was initially founded by a pharmaceutical chemist in 1876, has sold products to over one hundred and twenty-five countries and is a member of the EFPIA, also known as the European Federation of Pharmaceutical Industries and Associations.

About Eli Lilly and Company

Eli Lilly and Company is the largest manufacturer of psychiatric medications including Prozac, Zyprexa, and Cymbalta. In the same year of the joint venture with ICOS, the company came under new leadership, with former chief operating officer Sidney Taurel being named CEO in 1998. Ultimately this change in CEO was beneficial to the company’s growth, which exploded in 1999 and continued to rise.

The combined companies, as Lilly ICOS, LLC, continued studies on the drug for focused treatment of erectile dysfunction and found in 2002 that tadalafil was able to function for thirty-six hours, due to having a half-life of seventeen and a half hours. This made the drug much more effective than other competitors with similar products currently on the market like Viagra. This development was confirmed by the American Urological Association, and eventually led to FDA approval of the drug as treatment for erectile dysfunction.

Launch of Cialis

The drug Tadalafil, under the brand name Cialis, was first approved by the FDA to treat erectile dysfunction in 2003. Eli Lilly, the company that submitted the brand name “Cialis” purchased the pharmaceutical company ICOS, as well as the right to Cialis in the year 2007 for 2.3 billion dollars, or thirty-four dollars a share. This change in leadership meant that Eli Lilly now had full ownership of the drug Cialis, which lead to massive cutbacks within the company including large ICOS branches being shut down to make room for more growth.

 

Marketing & Advertisement

The marketing of Cialis has continually broken new ground, including women in its advertising campaign in contrast to the primarily male-driven ads of competitors like Viagra and Levitra. This in part lead to the widespread popularity of the medication, as well as the company’s commitment to include more true information about the drug in advertising and marketing material.

Cialis ads aired during the 2004 Super Bowl, and Cialis later came to sponsor many sports events like the PGA Tour and the America’s Cup. The overall marketing and advertising campaign designed and carried out by the Grey Worldwide Agency in New York popularised the drug for erectile dysfunction treatment, which then allowed it to grow even more in popularity due to its advantages over other similar drugs, including its significantly longer half-life.

Cialis Today

In later years, the drug tadalafil, which makes up Cialis, was also approved by the FDA as a medical treatment for symptoms of BPH, or benign prostatic hyperplasia. These symptoms include difficulty urinating or, on the flip side, sudden urges to urinate, as well as increase in frequency of urination and weak urine stream. The conditions of BPH and erectile dysfunction often appear as comorbid conditions, and tadalafil has also been approved to treat them concurrently.

About Irfana KoitaDr Koita is our lead fertility consultant with over 12 years of experience in the field of assisted reproduction, having trained at the renowned King’s College Hospital, London and subsequently gained a wealth of experience working at some of UK’s leading fertility clinics including CRGH, CARE Fertility and CREATE Fertility. Her special interest lies in the treatment of women who have suboptimal ovarian function using Natural Cycle IVF treatment and in those who have had multiple unsuccessful attempts. Her clientele includes women who wish to have Egg Freezing.Irfana Koita Facebook Irfana Koita Google Plus Irfana Koita Twitter Irfana Koita Medium Irfana Koita Wordpress Irfana Koita Blogger